RETURNING TO IMMUNOTHERAPY IN KIDNEY CANCER

被引：0
|
作者：
Kollmannsberger, C. [1 ]
机构：
[1] Univ British Columbia, Dept Med, British Columbia Canc Agcy, Div Med Oncol, Vancouver, BC, Canada
来源：
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 10卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
20
引用
收藏
页码：29 / 29
页数：1
相关论文
共 50 条
  • [11] Modern approaches to kidney cancer immunotherapy
    Kushlinskii, N. E.
    Fridman, M. V.
    Morozov, A. A.
    Gershtein, E. S.
    Kadagidze, Z. G.
    Matveev, V. B.
    ONKOUROLOGIYA, 2018, 14 (02): : 54 - 67
  • [12] Immunotherapy for kidney cancer: status quo and the future
    Bedke, Jens
    Stuehler, Viktoria
    Stenzl, Arnulf
    Brehmer, Bernhard
    CURRENT OPINION IN UROLOGY, 2018, 28 (01) : 8 - 14
  • [13] Novel emerging biomarkers to immunotherapy in kidney cancer
    Ged, Yasser
    Voss, Martin H.
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13
  • [14] Acute Kidney Injury in Cancer Immunotherapy Recipients
    Joseph, Adrien
    Lafarge, Antoine
    Azoulay, Elie
    Zafrani, Lara
    CELLS, 2022, 11 (24)
  • [15] Combination immunotherapy promising for treatment of kidney cancer
    不详
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2018, 14 (02) : 246 - 246
  • [16] Combination immunotherapy approved for kidney cancer in the UK
    不详
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2019, 15 (06) : 1204 - 1204
  • [17] Immunotherapy in kidney cancer: the past, present, and future
    Hammers, Hans
    CURRENT OPINION IN UROLOGY, 2016, 26 (06) : 543 - 547
  • [18] Evaluating the Optimal Duration of Immunotherapy in Kidney Cancer
    Parikh, Mamta
    Lara, Primo N.
    KIDNEY CANCER, 2022, 6 (02) : 105 - 107
  • [19] Immunotherapy in Kidney Cancer: A Clinical-Translational Perspective
    Kim, William
    INTERNATIONAL JOURNAL OF UROLOGY, 2018, 25 : 108 - 108
  • [20] Checkmate: kidney injury associated with targeted cancer immunotherapy
    Perazella, Mark A.
    KIDNEY INTERNATIONAL, 2016, 90 (03) : 474 - 476
12345